Guidelines for the Diagnosis and Treatment of Hidradenitis Suppurativa in the UAE: A Consensus from the Emirates Dermatology Society - Report - MDSpire
Advertisement
Guidelines for the Diagnosis and Treatment of Hidradenitis Suppurativa in the UAE: A Consensus from the Emirates Dermatology Society
Clinical Report: Guidelines for Hidradenitis Suppurativa in the UAE
Overview
This report presents the first region-specific guidelines for diagnosing and managing hidradenitis suppurativa (HS) in the UAE, developed through a modified Delphi methodology involving 14 experts. The guidelines emphasize early intervention, lifestyle modifications, and a multidisciplinary approach to improve patient outcomes.
Background
Hidradenitis suppurativa is a chronic inflammatory skin condition that significantly impacts patients' quality of life and mental health. The prevalence of HS is challenging to estimate, particularly in the UAE, where regional disparities in care exist. Establishing localized guidelines is essential to address these challenges and provide standardized, evidence-based treatment options.
Data Highlights
No numerical data available in the source material.
Key Findings
The consensus includes 58 statements tailored to the UAE's clinical and demographic landscape.
Recommendations emphasize early intervention and lifestyle modifications for HS management.
Comorbidity screening for metabolic and inflammatory conditions is crucial in HS patients.
A stepwise treatment approach incorporating topical agents, systemic antibiotics, biologics, and surgical options is advocated.
Multidisciplinary care, including psychological support, is essential for comprehensive HS management.
Clinical Implications
Healthcare providers in the UAE should adopt these guidelines to standardize HS care and improve treatment outcomes. Emphasizing early intervention and a multidisciplinary approach can address the complex needs of HS patients effectively.
Conclusion
The establishment of region-specific guidelines for HS in the UAE marks a significant step towards improving patient care and outcomes. These recommendations aim to reduce variability in treatment and enhance the overall management of this challenging condition.
Secukinumab becomes the only interleukin-17A inhibitor approved for pediatric patients aged 12 years and older with moderate to severe hidradenitis suppurativa.
